公开(公告)号：US20090042931A1

公开(公告)日：2009-02-12

申请号：US11918240

申请日：2006-04-12

Applicant: Mathias Alterman ,  Anders Hallberg ,  Xiongyu Wu

Inventor： Mathias Alterman ,  Anders Hallberg ,  Xiongyu Wu

IPC: A61K31/4178 ,  A61P1/00 ,  A61P9/00 ,  C07D409/10 ,  A61K31/4155 ,  A61K31/437 ,  C07D471/04 ,  A61K31/4184 ,  A61P11/00 ,  A61P25/00

CPC classification number: C07D409/10

Abstract: There is provided compounds of formula I, wherein A, X1, X2, X3, X4, Y1, Y2, Y3, Y4, Z1, Z2, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.

Abstract translation: 提供式I化合物，其中A，X 1，X 2，X 3，X 4，Y 1，Y 2，Y 3，Y 4，Z 1，Z 2，R 4和R 5具有说明书中给出的含义及其药学上可接受的盐， 作为AT2受体的选择性激动剂是有用的，因此特别是用于治疗尤其是消化不良，IBS和MOF以及心血管疾病的胃肠道疾病。

公开(公告)号：US20120202853A1

公开(公告)日：2012-08-09

申请号：US13500341

申请日：2010-10-06

Applicant: Joakim Löfstedt ,  Xiongyu Wu ,  Lars Krüger

Inventor： Joakim Löfstedt ,  Xiongyu Wu ,  Lars Krüger

IPC: A61K31/4439 ,  A61K31/4155 ,  A61K31/415 ,  C07D231/38 ,  C07D413/04 ,  C07D403/04 ,  C07D405/04 ,  A61K31/422 ,  C07D401/04

CPC classification number: C07D231/12 ,  C07D207/416 ,  C07D231/38 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  C07D409/04 ,  C07D413/04 ,  C07D413/14

Abstract: The invention provides a compound of formula (I) wherein G is a pyrazole ring as defined in the specification and R4, R5, R6 and R7 are as defined in the specification; or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.

Abstract translation: 本发明提供式（I）化合物，其中G是说明书中定义的吡唑环，R4，R5，R6和R7如说明书中所定义; 或其药学上可接受的酯，酰胺，溶剂合物或其盐，包括这种酯或酰胺的盐，以及这种酯，酰胺或盐的溶剂合物。 本发明还提供了这样的化合物在治疗或预防与与雌激素受体活性相关的疾病或病症相关的病症中的用途。

公开(公告)号：US08080571B2

公开(公告)日：2011-12-20

申请号：US11918240

申请日：2006-04-12

Applicant: Mathias Alterman ,  Anders Hallberg ,  Xiongyu Wu

Inventor： Mathias Alterman ,  Anders Hallberg ,  Xiongyu Wu

IPC: A61K31/4155 ,  A61K31/4174 ,  A61K31/4178 ,  A61K31/4192 ,  C07D233/54 ,  C07D249/06 ,  C07D231/10

CPC classification number: C07D409/10

Abstract: There is provided compounds of formula I, wherein A, X1, X2, X3, X4, Y1, Y2, Y3, Y4, Z1, Z2, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.

Abstract translation: 提供式I化合物，其中A，X 1，X 2，X 3，X 4，Y 1，Y 2，Y 3，Y 4，Z 1，Z 2，R 4和R 5具有说明书中给出的含义及其药学上可接受的盐， 作为AT2受体的选择性激动剂是有用的，因此特别是用于治疗尤其是消化不良，IBS和MOF以及心血管疾病的胃肠道疾病。

公开(公告)号：US20200239412A1

公开(公告)日：2020-07-30

申请号：US16651260

申请日：2018-09-27

Applicant: Fredrik ELINDER ,  Xiongyu WU ,  Nina OTTOSSON ,  Peter KONRADSSON ,  Malin SILVERÅ EJNEBY

Inventor： Fredrik ELINDER ,  Xiongyu WU ,  Nina OTTOSSON ,  Peter KONRADSSON ,  Malin SILVERÅ EJNEBY

IPC: C07C305/18 ,  C07F9/09 ,  C07C309/14 ,  C07C309/04 ,  C07C233/63 ,  C07C233/62 ,  C07C57/50

Abstract: Dehydroabietic acid derivatives according to Formula Ia or Formula Ib and all stereoisomers thereof, having a linker chain A of 1 to 10 atoms selected from carbon, nitrogen and oxygen to a group X capable of being negatively charged at a physiological pH and covalently attached to the linker chain A, selected from carboxyl, sulfate, sulfonate and phosphate groups. The Dehydroabietic acid derivatives are useful for therapeutic treatment of hyperexcitability diseases

公开(公告)号：US20090215847A1

公开(公告)日：2009-08-27

申请号：US11918238

申请日：2006-04-12

Applicant: Mathias Alterman ,  Anders Hallberg ,  Xiongyu Wu

Inventor： Mathias Alterman ,  Anders Hallberg ,  Xiongyu Wu

IPC: A61K31/4178 ,  A61K31/4025 ,  A61P1/04 ,  C07D409/02

CPC classification number: C07D409/10

Abstract: There is provided compounds of formula I, wherein the dotted line, X1, X2, X3, A, Y1, Y2, Y3, Y4, Z1, Z2, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.

Abstract translation: 提供式I化合物，其中虚线X1，X2，X3，A，Y1，Y2，Y3，Y4，Z1，Z2，R2和R3具有说明书中给出的含义及其药学上可接受的盐， 哪些化合物可用作AT2受体的选择性激动剂，因此特别是用于治疗尤其是消化不良，IBS和MOF以及心血管疾病的胃肠道疾病。

公开(公告)号：US08653112B2

公开(公告)日：2014-02-18

申请号：US13500341

申请日：2010-10-06

Applicant: Joakim Löfstedt ,  Xiongyu Wu ,  Lars Krüger

Inventor： Joakim Löfstedt ,  Xiongyu Wu ,  Lars Krüger

IPC: A61K31/4439 ,  A61K31/4155 ,  A61K31/415 ,  C07D231/38 ,  C07D413/04 ,  C07D403/04 ,  C07D405/04 ,  A61K31/422 ,  C07D401/04

CPC classification number: C07D231/12 ,  C07D207/416 ,  C07D231/38 ,  C07D401/04 ,  C07D403/04 ,  C07D405/04 ,  C07D409/04 ,  C07D413/04 ,  C07D413/14

Abstract: The invention provides a compound of formula (I) wherein G is a pyrazole ring as defined in the specification and R4, R5, R6 and R7 are as defined in the specification; or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.

公开(公告)号：US08067418B2

公开(公告)日：2011-11-29

申请号：US11918238

申请日：2006-04-12

Applicant: Mathias Alterman ,  Anders Hallberg ,  Xiongyu Wu

Inventor： Mathias Alterman ,  Anders Hallberg ,  Xiongyu Wu

IPC: A61K31/41 ,  C07D235/12 ,  C07D235/14 ,  C07D239/02 ,  C07D241/02 ,  C07D333/02

CPC classification number: C07D409/10

Abstract: There is provided compounds of formula I, wherein the dotted line, X1, X2, X3, A, Y1, Y2, Y3, Y4, Z1, Z2, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions, such as dyspepsia, IBS and MOF, and cardiovascular disorders.

Abstract translation: 提供式I化合物，其中虚线X1，X2，X3，A，Y1，Y2，Y3，Y4，Z1，Z2，R2和R3具有说明书中给出的含义及其药学上可接受的盐， 哪些化合物可用作AT2受体的选择性激动剂，因此特别是用于治疗尤其是消化不良，IBS和MOF以及心血管疾病的胃肠道疾病。

公开(公告)号：US20100210524A1

公开(公告)日：2010-08-19

申请号：US12452678

申请日：2008-07-21

Applicant: Theresa Apelqvist ,  Joakim Löfstedt ,  Thomas Norin ,  Mattias Wennerstål ,  Xiongyu Wu ,  Lars Hagberg

Inventor： Theresa Apelqvist ,  Joakim Löfstedt ,  Thomas Norin ,  Mattias Wennerstål ,  Xiongyu Wu ,  Lars Hagberg

IPC: A61K31/122 ,  C07C49/747 ,  C07C255/47 ,  A61K31/277 ,  C07C251/44 ,  A61K31/15 ,  C07C233/33 ,  A61K31/167 ,  C07D333/38 ,  A61K31/381 ,  C07D307/46 ,  A61K31/341 ,  C07D277/34 ,  A61K31/426 ,  C07D207/333 ,  A61K31/40 ,  C07C69/78 ,  A61K31/235 ,  C07D261/08 ,  A61K31/42 ,  C07C211/45 ,  A61K31/136 ,  C07D231/56 ,  A61K31/416 ,  C07D407/10 ,  C07D209/52 ,  A61K31/403 ,  C07C311/08 ,  A61K31/18 ,  C07C311/21 ,  A61K31/663 ,  A61K31/565 ,  A61K38/23 ,  A61K31/59 ,  A61P35/00 ,  A61P37/06 ,  A61P25/00 ,  A61P19/00 ,  A61P19/10 ,  A61P3/04 ,  A61P3/06 ,  A61P9/00 ,  A61P15/00

CPC classification number: C07C49/747 ,  C07C45/513 ,  C07C45/62 ,  C07C45/63 ,  C07C45/65 ,  C07C45/66 ,  C07C45/673 ,  C07C45/676 ,  C07C45/68 ,  C07C45/69 ,  C07C45/71 ,  C07C45/72 ,  C07C45/78 ,  C07C49/753 ,  C07C49/84 ,  C07C69/63 ,  C07C225/22 ,  C07C233/33 ,  C07C251/44 ,  C07C255/47 ,  C07C311/08 ,  C07C311/21 ,  C07C2601/02 ,  C07C2602/22 ,  C07C2602/30 ,  C07D207/333 ,  C07D209/44 ,  C07D209/94 ,  C07D231/56 ,  C07D261/08 ,  C07D277/24 ,  C07D277/34 ,  C07D307/46 ,  C07D307/52 ,  C07D333/16 ,  C07D333/22 ,  C07D333/38 ,  C07C49/633

Abstract: The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt, wherein W, X, Y, Z, R1, R2, R7, R8, R9, R10, R11, R12, R13, R14, R15 and R16 are as defined in the specification. The invention also provides also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.

Abstract translation: 本发明提供式（I）化合物或其药学上可接受的酯，酰胺，溶剂合物或其盐，包括这种酯或酰胺的盐，以及这种酯，酰胺或盐的溶剂合物，其中W，X， Y，Z，R 1，R 2，R 7，R 8，R 9，R 10，R 11，R 12，R 13，R 14，R 15和R 16如说明书中所定义。 本发明还提供了这样的化合物在治疗或预防与雌激素受体活性相关的疾病或病症相关的病症中的用途。